As a glucagon-like peptide-1, or GLP-1, agonist, semaglutide targets one hormone
1 This was the first time any weight-loss medication had demonstrated a reduction in cardiovascular risk in a large-scale trial
Most patients see measurable changes in their body composition around three to four weeks into their plan, with a steady fat loss of 0.51.5 lbs per week from weeks five to eight, especially when pairing AOD 9604 with nutrition and training
12:301:30 pm CDT 782-P Once-Weekly Semaglutide vs
Retrieved from Center for Drug Evaluation and Research
Without baseline labs, clinicians risk missing underlying conditions (e.g., insulin resistance, fatty liver, thyroid dysfunction) that influence both safety and treatment outcomes